Follow TPIMS:

  • Facebook: tpims
  • Linked In: company/torrey-pines-institute-for-molecular-studies
  • Twitter: tpims
  • External Link:
Meet Our California Scientists Brigitte Dudouet
  Untitled Document Share

Brigitte Dudouet

 Brigitte DudouetTorreyPinesInstituteCA

Adjunct Associate Member
Cancer Research

858.597.3843 - phone
858.597.3804 - fax
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Our research focus is to develop new and effective immunotherapy approaches targeting angiogenesis in solid tumors of different types of cancer. Immunotherapy is an approach to treat cancer that harnesses our own immune system. White blood cells called T cells are taught to recognize proteins on the surface of tumor cells, which they use to bind to and kill cancer cells, while sparing normal cells. However, there are limitations to this approach; the tumors can be inaccessible to T cells, and tumor cells can stop expressing the targeted protein. If this happens, the tumor becomes resistant to T cell attack. To circumvent these problems, our goal is to develop therapeutic approaches involving the immune system, targeting in a specific manner solid tumor vessels instead of the tumor cells.

Dr. Brigitte Dudouet’s laboratory is developing cancer vaccines that target the established prostate tumour vasculature. Angiogenesis is a process by which new vessels arise from the pre-existing vasculature. It is a required step for prostate tumour and metastasis growth, which gives strong therapeutic value to any agents targeting this process. Tumour blood vessels express characteristic markers (Tumour Endothelial Markers or TEMs), that are absent from normal vessels, and these can be used as targets for immunotherapy strategies. Dr. Dudouet‘s laboratory has developed dendritic cell-based vaccines composed of autologous dendritic cells pulsed ex vivo with the tumour endothelial markers of interest. These vaccines are currently being tested in pre-clinical animal models for prostate cancer, such as the TRAMP mice (Transgenic Adenocarcinoma of the Mouse Prostate).  If the preclinical models show them to be effective and non-toxic, these vaccines can be brought to clinical trials. The long-term goal of this study is to develop novel, well tolerated, and effective vaccines for prostate cancer that will reduce the need for chemotherapy, improve patients’ quality of life, and prolong survival.

Dr. Dudouet earned her Pharm. D. (Pharmaceutical Degree-Specialization Medical Biology) in 1979 from La Timone School of Pharmacy, University of Aix-Marseille II, France. Between 1979 and 1981, she completed her studies in Marine Pharmacology/Organic Chemistry at the Oceanographic Center of Marseille, Lumigny University, and the Institut de Chimie des Substances Naturelles of Gif sur Yvette, Paris. Between 1981 and 1985, she held a position of Assistant Professor (Clinical Biology/Biochemistry) at the (CHU) University and Hospital Complex of St Antoine, Pierre and Marie Curie University, Paris VI, teaching and pursuing research in biochemistry at St Antoine Medical School, while having the function of deputy director of the medical biochemistry laboratory of the Rotshild Hospital (Paris). In 1985, Dr. Dudouet joined the Pasteur Institute (Paris) and obtained a tenure position of scientist in the Cellular Biology department. She devoted her time to basic and clinical research on colorectal cancer from 1985 to 1994. She earned her Ph.D. in Immunology from Pierre and Marie Curie University, Paris VI in 1992. She moved to United States in July 1994 and worked as a visiting scientist at The Scripps Research Institute, the R.W. Johnson Pharmaceutical Research Institute and UCSD between 1994 and 1998 and specialized in innate immunity and cancer vaccine.  In 1998, after a brief return to the Pasteur Institute, she joined The Sidney Kimmel Cancer Center as a scientist and resigned from her tenure position at the Pasteur Institute in 1999. Her research focus was mainly on cancer, cancer vaccine, angiogenesis and tumor vascular targeting. Dr. Dudouet joined the Torrey Pines Institute for Molecular Studies as a Principal Investigator (Associate Member) in June 2006.


  • 1992 – Ph.D. Immunology, Pierre & Marie Curie University, Paris 6, France.
  • 1981-M.S.Master in Oceanography, Lumigny University, Marseille, France.
  • 1979 -Pharmaceutical Doctorate (Pharm.D.), Timone University, Marseille, France

Academic Positions

  • June 2006-present: Associate Member, Torrey Pines Institute for Molecular Studies, La Jolla San Diego.
  • 2003-2006: Senior Research Scientist. Vascular Biology Department.  Sidney Kimmel Cancer Center, La Jolla, San Diego.
  • 2002-2003: Senior Research Associate. Molecular Biology Department. The Scripps Research Institute. La Jolla, San Diego.
  • 1999-2002: Research Scientist. Vascular Biology Department Sidney Kimmel Cancer Center. La Jolla, San Diego
  • 1994 – 1999 Research Scientist (tenure position) Pasteur Institute. Paris and Visiting Scientist in United States at:
  • 1998-1999 Sidney Kimmel Cancer Center, San Diego
  • 1997-1998 UCSD Cancer Center, San Diego
  • 1995-1997 The R.W.Johnson Pharmaceutical Research Institute, Division of Cellular Therapy. San Diego
  • 1994-1995 The Scripps Research Institute. Department of Immunology. San Diego
  • 1985-1994 Research Scientist (tenure position). Department of Cellular Biology. Pasteur Institute. Paris .
  • 1981–1985 Assistant Professor (Medical Biochemistry). St Antoine Medical School of Pierre and Marie Curie University (Paris VI). Paris. France
  • 1980-1981 Fellowship Award from the C.N.R.S. ( National Center for Scientific Research) Paris. France.

Selected Publications (10 of 19)

  1. Gregory I. Frost, Joseph Lustgarten, Brigitte Dudouet, Lynda Nyberg, Beryl Hartley-Asp, Per Borgstrom. Novel syngeneic pseudo-orthotopic prostate cancer Model: vascular, mitotic and apoptotic responses to castration. Microvascular Research 2005 Jan; 69(1-2):1-9.
  2. Dudouet, B., Burnett, R., R.., Dickinson, L.A., Wood., Melander,C., Beltsky, J.M.Edelson, B., Dervan, P.B., Gottesfeld, J.M. Accessibility of nuclear chromatin by DNA binding polyamides. Chem. Biol. 2003 Sept; 10 (9): 859-67
  3. Frost GI, Dudouet B, Lustgarten J & Borgström P. The roles of epithelial-mesynchymal interactions and the innate immune response on the tumorigenicity of human prostate carcinoma cell lines grown in immuno-compromised mice. In Vivo. 2003 Sep-Oct; 17 (5):377-88.
  4. Minev, B.R., Chavez, F.L., Dudouet, B., and Mitchell, M.S.. (2000). Synthetic signal sequences enhance class I presentation of a peptide from melanoma antigen mart-1. Eur J.  Immunol. 30:2115-2124.
  5. Dudouet, B., Aznard, C., Boisson, M., Mousson, L., Mazie, J.C., Louvard, D., and Garrigue G. (1991). Villin an enterocyte cytoskeletal protein, in diagnosis and follow up of colorectal cancers.  Comparison with carcinoembryonic antigen. Acta Endoscopica. N°1/ Volume 21.
  6. Dudouet, B., Jacob, L., Beuzeboc, P., Magdelénat, H., Robine, S., Chapuis, Y., Christoforov, Y., Cremer, G.A., Pouillard, P., Bonnichon, P., Pointereau, A., Bellanger, J., Maunoury, M., and Louvard, D. (1990).  Presence of villin, a cytoskeletal protein, in sera of patients.  An initial clinical evaluation of its value for the diagnosis and follow up of colorectal cancers. Cancer Research. 50:438-443.
  7. M. Arpin, L. Blair, E. Coudrier, B. Dudouet, J. Finidori, A. Garcia, C. Huet, E.Pringault, S. Robine, C. Sahuquillo-Mérino & D. Louvard. Villin, a specific marker for some epithelia specialized in transport, to study the differentiation of intestinal and kidney cells in vivo and in a human colon adenocarcinoma line HT 29 in culture. Molecular Aspects Medecine,Pergamon Press plc.(1988);10(3)  257-272.
  8. Dudouet, B., Robine, S., Huet, C., Sahuquillo-Mérino, C., Blair, L., Coudrier, E., and Louvard, D.  (1987). Change in villin synthesis and subcellular distribution during intestinal differentiation of HT29-18 clones. J. Cell Biol. 105:359-369.
  9. Moll, R., Robine, S., Dudouet, B., and Louvard, D. (1987). Villin: A cytoskeletal protein and an early differentiation marker that is expressed in some human adenocarcinomas. Virchows Archiv. 54:155-169.
  10. Figiel, A., Schilt, J., Dudouet, B., Robine, S., and Dauca, M.. (1987). Stage-specific polypeptides and villin expression during the intestinal epithelium substitution of the metamorphosing amphibian.  Differentiation. 36:116-124.

  1. Antibodies which recognize and bind human villin. U.S. Patent No. 5,635,389. Issued June 3, 1997.   Inventors:  Louvard, D., Dudouet, B., Robine, S., Arpin, M., Pringault, E., Garcia, A.
  2. Agents for the in vitro diagnosis of malignant cells originating in the digestive tract. U.S. Patent No. 5,188,967. Issued February 23, 1993.   Inventors:  Louvard, D., Dudouet, B., Arpin, M., Pringault, E., Garcia, A.